{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T17:22:30Z","timestamp":1758043350491,"version":"3.44.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T00:00:00Z","timestamp":1757635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Interventions to delay or prevent the onset of rheumatoid arthritis (RA) have attracted much attention in recent years. Researchers are now exploring various prevention strategies but no unified consensus was reached. A traditional Chinese medicine (TCM) prescription, Formulation A (FA), may be potential to reduce the risk of RA development.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This is a multicenter, double-blind, placebo-controlled, randomized clinical trial. We will enroll 72 participants who are positive for anti-cyclic citrullinated peptide (anti-CCP) antibody but without synovitis. Participants will be randomly assigned to either FA or placebo for 52 weeks. All will then undergo 52 weeks of observation. The primary outcome is the time interval between the study entry and RA diagnosis. The secondary outcomes include the proportions of RA diagnosis, anti-CCP antibody, rheumatoid factor (RF), the high-sensitivity C-reactive protein (hs-CRP), the erythrocyte sedimentation rate (ESR), the 28-tender joint count (TJC28), the 28-swollen joint count (SJC28), morning stiffness time, the visual analog scale (VAS), Patient\u2019s Global Assessment (PtGA), Physician\u2019s Global Assessment (PGA), Health Assessment Questionnaire (HAQ), Generic Quality of Life Inventory-74 (GQOLI-74) scores, and ultrasound images of joints.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>This study attempts to test the feasibility of a clinical trial using FA in RA prevention. It will lay the foundation for future research and ensure validity.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2025.1623474","type":"journal-article","created":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T05:34:49Z","timestamp":1757655289000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Formulation A in the prevention of rheumatoid arthritis: a study protocol for a multicenter randomized controlled trial"],"prefix":"10.3389","volume":"12","author":[{"given":"Kaixin","family":"Gao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yihang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianhong","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weidong","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengdong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongliang","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liyan","family":"Mei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haifang","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiumin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maojie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zehuai","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aikaterini","family":"Chatzidionysiou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Per-Johan","family":"Jakobsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Runyue","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1056\/NEJMra1004965","article-title":"The pathogenesis of rheumatoid arthritis.","volume":"365","author":"McInnes","year":"2011","journal-title":"N Engl J Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1136\/annrheumdis-2011-200990","article-title":"EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the study group for risk factors for rheumatoid arthritis.","volume":"71","author":"Gerlag","year":"2012","journal-title":"Ann Rheum Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1136\/annrheumdis-2016-209846","article-title":"EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis.","volume":"76","author":"van Steenbergen","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.jbspin.2019.11.009","article-title":"Origins of rheumatoid arthritis.","volume":"87","author":"Boissier","year":"2020","journal-title":"Joint Bone Spine"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis.","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41590-020-00816-x","article-title":"The immunology of rheumatoid arthritis.","volume":"22","author":"Weyand","year":"2021","journal-title":"Nat Immunol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1002\/art.11223","article-title":"Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis.","volume":"48","author":"Rantap\u00e4\u00e4-Dahlqvist","year":"2003","journal-title":"Arthritis Rheum"},{"key":"B8","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1136\/ard.2009.120899","article-title":"Smoking is a major preventable risk factor for rheumatoid arthritis: estimations of risks after various exposures to cigarette smoke.","volume":"70","author":"K\u00e4llberg","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"B9","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1146\/annurev.immunol.26.021607.090244","article-title":"Immunity to citrullinated proteins in rheumatoid arthritis.","volume":"26","author":"Klareskog","year":"2008","journal-title":"Annu Rev Immunol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1002\/eji.202048952","article-title":"Towards prevention of autoimmune diseases: the example of rheumatoid arthritis.","volume":"51","author":"Hensvold","year":"2021","journal-title":"Eur J Immunol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1111\/joim.13537","article-title":"Where traditional Chinese medicine meets Western medicine in the prevention of rheumatoid arthritis.","volume":"292","author":"Jakobsson","year":"2022","journal-title":"J Intern Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"686360","DOI":"10.3389\/fphar.2021.686360","article-title":"The effect of Chinese medicine compound in the treatment of rheumatoid arthritis on the level of rheumatoid factor and anti-cyclic citrullinated peptide antibodies: a systematic review and meta-analysis.","volume":"12","author":"Tang","year":"2021","journal-title":"Front Pharmacol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"914","DOI":"10.3389\/fphar.2018.00914","article-title":"The bone-protecting efficiency of chinese medicines compared with western medicines in rheumatoid arthritis: a systematic review and meta-analysis of comparative studies.","volume":"9","author":"Cai","year":"2018","journal-title":"Front Pharmacol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"4348709","DOI":"10.1155\/2020\/4348709","article-title":"Efficacy and safety of integrated traditional Chinese medicine and Western medicine on the treatment of rheumatoid arthritis: a meta-analysis.","volume":"2020","author":"Xing","year":"2020","journal-title":"Evid Based Complement Alternat Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e2300337","DOI":"10.1002\/jssc.202300337","article-title":"Characterization of chemical constituents in Huangqi Guizhi Wuwu decoction using ultra-high performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry.","volume":"46","author":"Fan","year":"2023","journal-title":"J Sep Sci."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e5715","DOI":"10.1002\/bmc.5715","article-title":"Comparison of IDA, SWATH, and MS(ALL) techniques in the analysis of compounds of Huangqi Guizhi Wuwu decoction by UHPLC-Q-TOF-MS.","volume":"37","author":"Fan","year":"2023","journal-title":"Biomed Chromatogr"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e5783","DOI":"10.1002\/bmc.5783","article-title":"Identification of the absorbed constituents and metabolites of Huangqi Guizhi Wuwu decoction by ultrahigh-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry.","volume":"38","author":"Fan","year":"2024","journal-title":"Biomed Chromatogr"},{"key":"B18","doi-asserted-by":"publisher","first-page":"7151634","DOI":"10.1155\/2020\/7151634","article-title":"Deciphering the molecular targets and mechanisms of HGWD in the treatment of rheumatoid arthritis via network pharmacology and molecular docking.","volume":"2020","author":"Liu","year":"2020","journal-title":"Evid Based Complement Alternat Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"5438","DOI":"10.19540\/j.cnki.cjcmm.20230516.201","article-title":"Research progress on Huangqi Guizhi Wuwu Decoction and predictive analysis of quality markers.","volume":"48","author":"Lu","year":"2023","journal-title":"Zhongguo Zhong Yao Za Zhi"},{"key":"B20","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12906-022-03826-4","article-title":"Exploration of the mechanism by which Huangqi Guizhi Wuwu decoction inhibits Lps-induced inflammation by regulating macrophage polarization based on network pharmacology.","volume":"23","author":"Wang","year":"2023","journal-title":"BMC Complement Med Ther."},{"key":"B21","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.chmed.2023.10.003","article-title":"Huangqi Guizhi Wuwu Decoction suppresses inflammation and bone destruction in collagen-induced arthritis mice.","volume":"16","author":"Bao","year":"2024","journal-title":"Chin Herb Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"6454","DOI":"10.19540\/j.cnki.cjcmm.20210902.703","article-title":"Mechanism of Huangqi Guizhi Wuwu Decoction in treatment of rheumatoid arthritis based on UPLC-LTQ-Orbitrap-MS, network pharmacology, and cell experiment.","volume":"46","author":"Lu","year":"2021","journal-title":"Zhongguo Zhong Yao Za Zhi."},{"key":"B23","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12906-023-04315-y","article-title":"Screening of the key response component groups and mechanism verification of Huangqi-Guizhi-Wuwu-Decoction in treating rheumatoid arthritis based on a novel computational pharmacological model.","volume":"24","author":"Liu","year":"2024","journal-title":"BMC Complement Med Ther"},{"key":"B24","doi-asserted-by":"publisher","first-page":"5013","DOI":"10.18632\/aging.203794","article-title":"Huangqi Guizhi Wuwu Decoction can prevent and treat oxaliplatin-induced neuropathic pain by TNFalpha\/IL-1beta\/IL-6\/MAPK\/NF-kB pathway.","volume":"14","author":"Li","year":"2022","journal-title":"Aging"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.4103\/1673-5374.189202","article-title":"Huangqi Guizhi Wuwu Decoction for treating diabetic peripheral neuropathy: a meta-analysis of 16 randomized controlled trials.","volume":"11","author":"Pang","year":"2016","journal-title":"Neural Regen Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.4103\/1673-5374.189202","article-title":"Study on the efficacy and safety of the Huangqi Guizhi Wuwu decoction in the prevention and treatment of chemotherapy-induced peripheral neuropathy: meta-analysis of 32 randomized controlled trials.","volume":"17","author":"Pang","year":"2024","journal-title":"J Pain Res"},{"key":"B27","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s13020-023-00826-5","article-title":"Huangqi Guizhi Wuwu decoction alleviates oxaliplatin-induced peripheral neuropathy via the gut-peripheral nerve axis.","volume":"18","author":"Zhang","year":"2023","journal-title":"Chin Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e31281","DOI":"10.1097\/MD.0000000000031281","article-title":"Huangqi Guizhi Wuwu decoction in peripheral neurotoxicity treatment using network pharmacology and molecular docking.","volume":"101","author":"Chen","year":"2022","journal-title":"Medicine"},{"key":"B29","first-page":"446","article-title":"Efficacy and safety of Huangqi Guizhi Wuwu decoction for oxaliplatin-induced peripheral neurotoxicity: a systematic review and meta-analysis.","volume":"30","author":"Yu","year":"2024","journal-title":"Altern Ther Health Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1080\/13880209.2019.1687526","article-title":"Coix lachryma-jobi extract ameliorates inflammation and oxidative stress in a complete Freund\u2019s adjuvant-induced rheumatoid arthritis model.","volume":"57","author":"Zhang","year":"2019","journal-title":"Pharm Biol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13020-023-00833-6","article-title":"Coix seed oil alleviates synovial angiogenesis through suppressing HIF-1alpha\/VEGF-A signaling pathways via SIRT1 in collagen-induced arthritis rats.","volume":"18","author":"Xu","year":"2023","journal-title":"Chin Med"},{"key":"B32","first-page":"26","article-title":"Meta-analysis on the efficacy and safety of Yiyiren Tang in the treatment of rheumatoid arthritis of cold dampness obstruction type (in Chinese).","volume":"11","author":"Yang","year":"2022","journal-title":"Rheumatism Arthritis."},{"key":"B33","doi-asserted-by":"publisher","first-page":"111937","DOI":"10.1016\/j.foodres.2022.111937","article-title":"Component analysis using UPLC-Q-Exactive Orbitrap-HRMS and quality control of Kudingcha (Ligustrum robustum (Roxb.) Blume).","volume":"162","author":"Ling","year":"2022","journal-title":"Food Res Int"},{"key":"B34","first-page":"371","article-title":"UPLC: a preeminent technique in pharmaceutical analysis.","volume":"69","author":"Kumar","year":"2012","journal-title":"Acta Pol Pharm."},{"key":"B35","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1007\/s11655-024-3760-2","article-title":"Targeting therapeutic windows for rheumatoid arthritis prevention.","volume":"30","author":"Gao","year":"2024","journal-title":"Chin J Integr Med"},{"key":"B36","author":"Chow","year":"2008","journal-title":"Sample Size Calculation in Clinical Research."},{"key":"B37","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1136\/ard.2009.119016","article-title":"Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial).","volume":"69","author":"Emery","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"B38","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1136\/annrheumdis-2011-201066","article-title":"Combination etanercept and methotrexate provides better disease control in very early (4 months and <2 years): post hoc analyses from the COMET study.","volume":"71","author":"Emery","year":"2012","journal-title":"Ann Rheum Dis"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1623474\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T05:34:51Z","timestamp":1757655291000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1623474\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,12]]},"references-count":38,"alternative-id":["10.3389\/fmed.2025.1623474"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1623474","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,12]]},"article-number":"1623474"}}